Arcellx (ACLX) Current Deferred Revenue (2021 - 2025)
Arcellx's quarterly Current Deferred Revenue came in at $56.0 million in Q4 2025, down 58.56% year-on-year from $135.1 million in Q4 2024, and down 6.33% quarter-over-quarter from $59.8 million in Q3 2025.
Arcellx has reported Current Deferred Revenue for 4 years, with the latest figure at $56.0 million in Q4 2025.
- For the quarter ending Q4 2025, Current Deferred Revenue fell 58.56% year-over-year to $56.0 million; the trailing twelve-month figure through Dec 2025 stood at $56.0 million (down 58.56% YoY), and the FY2025 full-year result was $56.0 million, down 58.56% from the prior year.
- Current Deferred Revenue for Q4 2025 stood at $56.0 million, down from $59.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $221.2 million in Q4 2023, with the low at $183000.0 in Q4 2021.
- Average Current Deferred Revenue over 4 years is $76.9 million, with a median of $59.8 million recorded in 2025.
- Year-over-year, Current Deferred Revenue sank 84.05% in 2024 and surged 296.27% in 2025.
- Tracing ACLX's Current Deferred Revenue over 4 years: stood at $183000.0 in 2021, then jumped by 120777.6% to $221.2 million in 2023, then slumped by 38.95% to $135.1 million in 2024, then tumbled by 58.56% to $56.0 million in 2025.
- The last three Current Deferred Revenue figures came in at $56.0 million (Q4 2025), $59.8 million (Q3 2025), and $59.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 55.97 Mn |
| Sep 30, 2025 | 59.75 Mn |
| Jun 30, 2025 | 59.32 Mn |
| Mar 31, 2025 | 57.37 Mn |
| Dec 31, 2024 | 135.05 Mn |
| Sep 30, 2024 | 69.87 Mn |
| Jun 30, 2024 | 14.97 Mn |
| Mar 31, 2024 | 31.19 Mn |
| Dec 31, 2023 | 221.21 Mn |
| Sep 30, 2023 | 94.18 Mn |
| Jun 30, 2023 | 93.88 Mn |
| Mar 31, 2023 | 107.29 Mn |
| Dec 31, 2021 | 183,000.00 |